CL2019001434A1 - Proteínas de unión a antígeno que se unen al receptor de leptina. (divisional solicitud 201800946) - Google Patents
Proteínas de unión a antígeno que se unen al receptor de leptina. (divisional solicitud 201800946)Info
- Publication number
- CL2019001434A1 CL2019001434A1 CL2019001434A CL2019001434A CL2019001434A1 CL 2019001434 A1 CL2019001434 A1 CL 2019001434A1 CL 2019001434 A CL2019001434 A CL 2019001434A CL 2019001434 A CL2019001434 A CL 2019001434A CL 2019001434 A1 CL2019001434 A1 CL 2019001434A1
- Authority
- CL
- Chile
- Prior art keywords
- antibodies
- lepr
- binding fragments
- antigen
- bind
- Prior art date
Links
- 102000025171 antigen binding proteins Human genes 0.000 title 1
- 108091000831 antigen binding proteins Proteins 0.000 title 1
- 102000005861 leptin receptors Human genes 0.000 title 1
- 108010019813 leptin receptors Proteins 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 6
- 102000036639 antigens Human genes 0.000 abstract 6
- 108091007433 antigens Proteins 0.000 abstract 6
- 239000012634 fragment Substances 0.000 abstract 6
- 230000011664 signaling Effects 0.000 abstract 3
- 206010070834 Sensitisation Diseases 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 208000006132 lipodystrophy Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008313 sensitization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
LA PRESENTE INVENCIÓN PROPORCIONA ANTICUERPOS Y FRAGMENTOS DE UNIÓN A ANTÍGENO DE ANTICUERPOS QUE SE UNEN AL RECEPTOR DE LEPTINA (LEPR), Y MÉTODOS DE USO DE LOS MISMOS. DE ACUERDO CON CIERTAS FORMAS DE REALIZACIÓN, LA INVENCIÓN INCLUYE ANTICUERPOS Y FRAGMENTOS DE UNIÓN A ANTÍGENO DE ANTICUERPOS QUE SE UNEN A [[PR Y ACTIVAN LA SEÑALIZACIÓN DE LEPR. EN OTRAS FORMAS DE REALIZACIÓN, LA INVENCIÓN INCLUYE ANTICUERPOS Y FRAGMENTOS DE UNIÓN A ANTÍGENO DE ANTICUERPOS QUE SE UNEN A LEPR Y POTENCIAN LA SENSIBILIZACIÓN DE LEPR A UN ANTÍGENO. EN CIERTAS FORMAS DE REALIZACIÓN, LA INVENCIÓN INCLUYE ANTICUERPOS Y FRAGMENTOS DE UNIÓN A ANTÍGENO DE ANTICUERPOS QUE SE UNEN A LEPR EN PRESENCIA Y AUSENCIA DE LEPTINA. EN CIERTAS FORMAS DE REALIZACIÓN, LA INVENCIÓN INCLUYE ANTICUERPOS Y FRAGMENTOS DE UNIÓN A ANTÍGENO DE ANTICUERPOS QUE INDUCEN LA SEÑALIZACIÓN EN CÉLULAS QUE EXPRESAN MUTANTES DE LEPR QUE DE OTRO MODO EXHIBEN UNA SEÑALIZACIÓN DEFICIENTE O DISMINUIDA EN PRESENCIA DE LEPTINA. LOS ANTICUERPOS Y FRAGMENTOS DE UNIÓN A ANTÍGENO DE LA PRESENTE INVENCIÓN SON ÚTILES PARA EL TRATAMIENTO DE LAS LIPODISTROFIAS Y OTRAS ENFERMEDADES Y TRASTORNOS ASOCIADOS O CAUSADOS POR LA DEFICIENCIA DE LEPTINA O LA RESISTENCIA A LA LEPTINA.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562240021P | 2015-10-12 | 2015-10-12 | |
| US201662359757P | 2016-07-08 | 2016-07-08 | |
| US201662375495P | 2016-08-16 | 2016-08-16 | |
| US201662393143P | 2016-09-12 | 2016-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019001434A1 true CL2019001434A1 (es) | 2019-10-11 |
Family
ID=57184864
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000946A CL2018000946A1 (es) | 2015-10-12 | 2018-04-12 | Proteínas de unión a antigeno que activan el receptor de leptina |
| CL2019001434A CL2019001434A1 (es) | 2015-10-12 | 2019-05-28 | Proteínas de unión a antígeno que se unen al receptor de leptina. (divisional solicitud 201800946) |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2018000946A CL2018000946A1 (es) | 2015-10-12 | 2018-04-12 | Proteínas de unión a antigeno que activan el receptor de leptina |
Country Status (33)
| Country | Link |
|---|---|
| US (5) | US10023644B2 (es) |
| EP (2) | EP3362477B1 (es) |
| JP (5) | JP7034068B2 (es) |
| KR (1) | KR20180070609A (es) |
| CN (1) | CN108368177B (es) |
| AU (2) | AU2016338851B2 (es) |
| BR (1) | BR112018007318A2 (es) |
| CA (1) | CA3000215A1 (es) |
| CL (2) | CL2018000946A1 (es) |
| CO (1) | CO2018003852A2 (es) |
| CY (1) | CY1125102T1 (es) |
| DK (1) | DK3362477T3 (es) |
| EA (1) | EA201890928A1 (es) |
| ES (1) | ES2908574T3 (es) |
| HK (1) | HK1254862A1 (es) |
| HR (1) | HRP20220426T8 (es) |
| HU (1) | HUE058280T2 (es) |
| IL (3) | IL300961B2 (es) |
| LT (1) | LT3362477T (es) |
| MX (2) | MX2018004531A (es) |
| MY (1) | MY187975A (es) |
| PH (1) | PH12018500663A1 (es) |
| PL (1) | PL3362477T3 (es) |
| PT (1) | PT3362477T (es) |
| RS (1) | RS63061B1 (es) |
| SG (1) | SG10201913432RA (es) |
| SI (1) | SI3362477T1 (es) |
| SM (1) | SMT202200125T1 (es) |
| TW (3) | TWI752920B (es) |
| UA (1) | UA124419C2 (es) |
| UY (1) | UY36942A (es) |
| WO (1) | WO2017066204A1 (es) |
| ZA (1) | ZA201801975B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP3538554A1 (en) * | 2016-11-08 | 2019-09-18 | Regeneron Pharmaceuticals, Inc. | Antigen-binding proteins that antagonize leptin receptor |
| AU2018260992B9 (en) | 2017-05-05 | 2024-02-15 | Regeneron Pharmaceuticals, Inc. | Auto-injector |
| AU2018390811A1 (en) | 2017-12-18 | 2020-07-02 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof |
| EP3773713A1 (en) * | 2018-04-06 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | A leptin receptor agonist antibody for use in treating a metabolic dysfunction or hypoleptinemia |
| HUE062399T2 (hu) * | 2018-10-11 | 2023-10-28 | Sumitomo Chemical Co | Propilénoxid tisztítási rendszer és eljárás propilénoxid elõállítására |
| US20220049018A1 (en) * | 2019-01-31 | 2022-02-17 | Siemens Healthcare Diagnostics Inc. | Anti-naloxone and anti-naltrexone monoclonal antibodies and methods of production and use thereof |
| US20220288169A1 (en) * | 2019-05-24 | 2022-09-15 | The Board of Supervisors of Louisiana State University and Agriculyural and Mechanical College | Compositions and methods for the treatment and prevention of hypoglycemic complications |
| GB2600273B (en) * | 2019-07-02 | 2024-06-05 | Univ Shanghai Technology | Antibody to leptin receptor |
| CN114746848B (zh) | 2019-12-03 | 2023-08-04 | 美光科技公司 | 用于存储装置的高速缓存架构 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| CN116670170A (zh) | 2020-09-15 | 2023-08-29 | 瑞泽恩制药公司 | Lepr激动剂用于疼痛的用途 |
| US20240153638A1 (en) | 2021-02-22 | 2024-05-09 | Regeneron Pharmaceuticals, Inc. | Method for diagnosing and treating partial lipodystrophy |
| CN114456124B (zh) * | 2021-12-30 | 2023-04-21 | 华南农业大学 | 一种新利司他半抗原、人工抗原、抗体及其制备方法和应用 |
| WO2024259313A1 (en) | 2023-06-16 | 2024-12-19 | Regeneron Pharamceuticals, Inc. | Medical device packaging and related methods |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451523B1 (en) | 1994-09-14 | 2002-09-17 | Interneuron Pharmaceuticals, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| US5643748A (en) | 1994-09-14 | 1997-07-01 | Progenitor, Inc. | HU-B1.219, a novel human hematopoietin receptor |
| US5912123A (en) | 1994-09-14 | 1999-06-15 | Progenitor, Inc. | Detection of the leptin receptor in reproductive organs and methods for regulating reproductive biology |
| US5856098A (en) | 1994-09-14 | 1999-01-05 | Progenitor, Inc. | Detection of a leptin receptor variant |
| US6977240B1 (en) * | 1995-11-27 | 2005-12-20 | Millenium Pharmaceuticals, Inc. | Methods of using the OB receptor antibodies to treat bodyweight disorders |
| US6482927B1 (en) | 1995-11-27 | 2002-11-19 | Millennium Pharmaceuticals, Inc. | Chimeric proteins comprising the extracellular domain of murine Ob receptor |
| US20020193571A1 (en) | 1996-01-08 | 2002-12-19 | Paul J. Carter | Wsx receptor agonist antibodies |
| US20050019325A1 (en) | 1996-01-08 | 2005-01-27 | Carter Paul J. | WSX receptor agonist antibodies |
| AU2476301A (en) | 1996-01-16 | 2001-05-24 | Rockefeller University, The | DB the receptor for leptin nucleic acids encoding the receptor, and uses thereof |
| AU1833197A (en) | 1996-01-18 | 1997-08-11 | Progenitor, Inc. | Detection of a leptin receptor variant and methods for regulating obesity |
| PT892849E (pt) | 1996-01-23 | 2006-08-31 | Indevus Pharmaceuticals Inc | Metodo para utilizacao do gene obeso e seu produto genico para estimular o desenvolvimento hematopoietico |
| AUPN780096A0 (en) * | 1996-01-30 | 1996-02-22 | Medvet Science Pty. Ltd. | Cytokine antagonists and agonists |
| IL120733A0 (en) | 1997-04-29 | 1997-08-14 | Yeda Res & Dev | Leptin as an inhibitor of cell proliferation |
| EP1542719A4 (en) * | 2001-12-05 | 2006-06-21 | Baylor College Medicine | METHOD AND COMPOSITIONS FOR CONTROLLING BONE CONSTRUCTION BY MODULATION OF THE SYMPATHICOTONUS |
| DE10353593A1 (de) * | 2003-11-17 | 2005-06-23 | Klinikum der Universität München Großhadern-Innenstadt | Leptinantagonist und Verfahren zur quantitativen Messung von Leptin |
| WO2005056602A1 (ja) * | 2003-12-12 | 2005-06-23 | Chugai Seiyaku Kabushiki Kaisha | アゴニスト活性を有する改変抗体のスクリーニング方法 |
| US7863240B2 (en) | 2004-10-08 | 2011-01-04 | Enzo Therapeutics, Inc. | Methods and uses of leptin in hepatocellular carcinoma |
| US8969291B2 (en) | 2004-10-08 | 2015-03-03 | Enzo Therapeutics, Inc. | Methods for decreasing leptin levels or activity for treating inflammation |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| EP1874816A4 (en) | 2005-04-26 | 2010-08-25 | Medimmune Inc | MODULATION OF THE ANTIBODY EFFECTOR FUNCTION BY "HINGE" DOMENGINE ENGINEERING |
| US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| HUE039337T2 (hu) | 2012-09-12 | 2018-12-28 | Genzyme Corp | Megváltozott glikolizációjú és csökkentett effektorfunkciójú, FC-t tartalmazó polipeptidek |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| TWI655207B (zh) * | 2013-07-30 | 2019-04-01 | 再生元醫藥公司 | 抗活化素ａ之抗體及其用途 |
| ES2831014T3 (es) | 2014-02-18 | 2021-06-07 | Inst Nat Sante Rech Med | Métodos y composiciones farmacéuticas para el tratamiento de enfermedades mediadas por la vía de señalización del complejo NRP-1/OBR |
| TWI752920B (zh) | 2015-10-12 | 2022-01-21 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| AU2018390811A1 (en) | 2017-12-18 | 2020-07-02 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen binding molecules that bind leptin receptor and/or GP130, and methods of use thereof |
-
2016
- 2016-10-07 TW TW105132493A patent/TWI752920B/zh active
- 2016-10-07 TW TW111100429A patent/TWI824372B/zh active
- 2016-10-07 TW TW112125041A patent/TW202417497A/zh unknown
- 2016-10-11 DK DK16785072.6T patent/DK3362477T3/da active
- 2016-10-11 CN CN201680072173.1A patent/CN108368177B/zh active Active
- 2016-10-11 JP JP2018518592A patent/JP7034068B2/ja active Active
- 2016-10-11 HR HRP20220426TT patent/HRP20220426T8/hr unknown
- 2016-10-11 KR KR1020187013185A patent/KR20180070609A/ko not_active Ceased
- 2016-10-11 IL IL300961A patent/IL300961B2/en unknown
- 2016-10-11 MY MYPI2018701183A patent/MY187975A/en unknown
- 2016-10-11 WO PCT/US2016/056465 patent/WO2017066204A1/en active Application Filing
- 2016-10-11 UY UY0001036942A patent/UY36942A/es not_active Application Discontinuation
- 2016-10-11 HU HUE16785072A patent/HUE058280T2/hu unknown
- 2016-10-11 PL PL16785072T patent/PL3362477T3/pl unknown
- 2016-10-11 EA EA201890928A patent/EA201890928A1/ru unknown
- 2016-10-11 LT LTEPPCT/US2016/056465T patent/LT3362477T/lt unknown
- 2016-10-11 EP EP16785072.6A patent/EP3362477B1/en active Active
- 2016-10-11 SM SM20220125T patent/SMT202200125T1/it unknown
- 2016-10-11 SG SG10201913432RA patent/SG10201913432RA/en unknown
- 2016-10-11 US US15/290,967 patent/US10023644B2/en active Active
- 2016-10-11 PT PT167850726T patent/PT3362477T/pt unknown
- 2016-10-11 SI SI201631477T patent/SI3362477T1/sl unknown
- 2016-10-11 MX MX2018004531A patent/MX2018004531A/es unknown
- 2016-10-11 EP EP21207469.4A patent/EP4071173A1/en active Pending
- 2016-10-11 UA UAA201803447A patent/UA124419C2/uk unknown
- 2016-10-11 CA CA3000215A patent/CA3000215A1/en active Pending
- 2016-10-11 IL IL316563A patent/IL316563A/en unknown
- 2016-10-11 RS RS20220294A patent/RS63061B1/sr unknown
- 2016-10-11 ES ES16785072T patent/ES2908574T3/es active Active
- 2016-10-11 AU AU2016338851A patent/AU2016338851B2/en active Active
- 2016-10-11 BR BR112018007318A patent/BR112018007318A2/pt active Search and Examination
-
2018
- 2018-03-26 PH PH12018500663A patent/PH12018500663A1/en unknown
- 2018-03-26 ZA ZA2018/01975A patent/ZA201801975B/en unknown
- 2018-03-29 IL IL258448A patent/IL258448B2/en unknown
- 2018-04-11 CO CONC2018/0003852A patent/CO2018003852A2/es unknown
- 2018-04-12 MX MX2023000738A patent/MX2023000738A/es unknown
- 2018-04-12 CL CL2018000946A patent/CL2018000946A1/es unknown
- 2018-06-13 US US16/007,848 patent/US10253102B2/en active Active
- 2018-06-13 US US16/007,812 patent/US10618968B2/en active Active
- 2018-11-01 HK HK18113959.2A patent/HK1254862A1/zh unknown
-
2019
- 2019-05-28 CL CL2019001434A patent/CL2019001434A1/es unknown
- 2019-10-04 US US16/593,761 patent/US20200031946A1/en not_active Abandoned
-
2021
- 2021-03-11 JP JP2021039405A patent/JP7165225B2/ja active Active
-
2022
- 2022-03-31 CY CY20221100249T patent/CY1125102T1/el unknown
- 2022-10-21 JP JP2022169008A patent/JP7436603B2/ja active Active
-
2023
- 2023-07-19 AU AU2023206125A patent/AU2023206125A1/en active Pending
- 2023-11-30 JP JP2023202680A patent/JP2024026230A/ja active Pending
-
2024
- 2024-02-09 JP JP2024018406A patent/JP2024042114A/ja active Pending
- 2024-08-20 US US18/810,454 patent/US20250051465A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019001434A1 (es) | Proteínas de unión a antígeno que se unen al receptor de leptina. (divisional solicitud 201800946) | |
| MX2024001803A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
| ECSP18095014A (es) | Proteínas de unión biespecíficas que se unen a una proteína inmunomoduladora y a un antígeno tumoral | |
| CY1123163T1 (el) | Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων | |
| DOP2020000128A (es) | Anticuerpos anti-trem2 y métodos relacionados | |
| CL2020003071A1 (es) | Proteínas de unión multiespecíficas y mejoras con estas | |
| CL2018003136A1 (es) | Proteínas de unión específica y usos de las mismas. | |
| ECSP18096095A (es) | Anticuerpos a la alfa-sinucleína y usos de los mismos | |
| MX383464B (es) | Anticuerpos anti-pd-1, anticuerpos anti-pd-1 activables, y métodos de uso de los mismos. | |
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| CU20170169A7 (es) | Anticuerpos de factor xi | |
| CL2021000516A1 (es) | Anticuerpos y/o fragmentos de los mismos que se unen específicamente a tau humano; ácidos nucleicos que los codifican; vector; células; método para producir los anticuerpos; composición farmacéutica; y uso de los mismos para inhibir la agregación de tau, y enfermedades asociadas (divisional de la solicitud no. 202001003) | |
| CR20170351A (es) | Proteínas de unión a icos | |
| MX351127B (es) | Proteínas de unión al antígeno del receptor de oncostatina m. | |
| MX2021007768A (es) | Anticuerpos anti-ctla4 y metodos de uso de los mismos. | |
| BR112017006468A2 (pt) | anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer | |
| UA123202C2 (uk) | Антитіло до тау-білка і його застосування | |
| CO2020000369A2 (es) | Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos | |
| MX2020011027A (es) | Constructos de anticuerpos biespecíficos trivalentes. | |
| BR112019000166A2 (pt) | anticorpos com baixa imunogenicidade e usos dos mesmos | |
| MX2016011177A (es) | Anticuerpos a la metaloproteinasa de matriz 9 y metodos de uso de los mismos. | |
| AR115992A2 (es) | Proteínas de unión a antígeno que activan el receptor de leptina | |
| AR118080A2 (es) | Proteínas de unión a antígeno dirigidas contra el receptor | |
| AR106198A1 (es) | Anticuerpos biespecíficos para la proteína de muerte celular programada 1 (pd1) y para la proteína humana que pertenece a la superfamilia de las inmunoglobulinas (tim3) | |
| AR106940A1 (es) | Anticuerpos anti claudina y métodos de uso |